Russian pharmaceutical company Pharmasynthes has announced that it will begin exporting medicines to Afghanistan this summer. The company says the first shipment of medicines will arrive in the country within the next two months, a move that could help boost the supply and diversity of health products amid the growing demand in the Afghan pharmaceutical market.
Publish dateSunday 31 May 2026 - 14:36
Story Code : 356428
Afghan Voice Agency (AVA) - Kabul: According to Nikita Punia, the company’s deputy commercial director, Afghanistan is one of the important markets for Pharmasynthes’ regional activities due to the growing need for medicines and health services. He expressed hope that this cooperation will expand in the future and become a sustainable framework for the supply of medicines.
The Russian company currently exports pharmaceuticals to 13 countries, including Syria, Myanmar, and the Dominican Republic, and plans to add new markets to its export list in 2026, including Afghanistan, Venezuela, Vietnam, Morocco, Bosnia and Herzegovina, Ecuador, and Mali.
Pharmasintiz produces more than 300 types of drugs and more than 60 pharmaceutical raw materials, with more than 80 percent of its products reportedly on the list of essential medicines. The company has several manufacturing plants in different cities in Russia, and its annual production capacity is said to be more than 100 million packages of medicines.
The entry of a large Russian pharmaceutical company into the Afghan market comes at a time when the country’s health sector is facing challenges such as a shortage of standard medicines, market fluctuations, and dependence on imports. In recent months, the issue of providing quality and affordable medicines has become one of the important issues in the Afghan health sector.
Health experts believe that increasing the diversity of imported sources can help improve market competition, reduce costs, and increase patients’ access to essential medicines. However, they emphasize that close monitoring of the quality and standards of imported medicines is essential to prevent the entry of substandard or unauthorized products.
In this regard, the Ministry of Public Health had earlier announced the visit of a high-level delegation to Russia, the purpose of which was to review and expand strategic cooperation in the field of procurement, regulation, and import of standard medicines.
The Russian company currently exports pharmaceuticals to 13 countries, including Syria, Myanmar, and the Dominican Republic, and plans to add new markets to its export list in 2026, including Afghanistan, Venezuela, Vietnam, Morocco, Bosnia and Herzegovina, Ecuador, and Mali.
Pharmasintiz produces more than 300 types of drugs and more than 60 pharmaceutical raw materials, with more than 80 percent of its products reportedly on the list of essential medicines. The company has several manufacturing plants in different cities in Russia, and its annual production capacity is said to be more than 100 million packages of medicines.
The entry of a large Russian pharmaceutical company into the Afghan market comes at a time when the country’s health sector is facing challenges such as a shortage of standard medicines, market fluctuations, and dependence on imports. In recent months, the issue of providing quality and affordable medicines has become one of the important issues in the Afghan health sector.
Health experts believe that increasing the diversity of imported sources can help improve market competition, reduce costs, and increase patients’ access to essential medicines. However, they emphasize that close monitoring of the quality and standards of imported medicines is essential to prevent the entry of substandard or unauthorized products.
In this regard, the Ministry of Public Health had earlier announced the visit of a high-level delegation to Russia, the purpose of which was to review and expand strategic cooperation in the field of procurement, regulation, and import of standard medicines.
avapress.net/vdchi-nx623nmkd.01t2.html
Top hits
1
